Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model

Korn, Paula and Kramer, Ina and Schlottig, Falko and Tödtmann, Ninette and Eckelt, Uwe and Bürki, Alexander and Ferguson, Stephen J. and Kautz, Armin and Schnabelrauch, Matthias and Range, Ursula and Kneissel, Michaela and Stadlinger, Bernd (2019) Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model. European Cells and Materials, 37. pp. 333-346. ISSN 1473-2262

Abstract

Osseointegration of dental implants can be promoted by implant-surface modifications using bisphosphonate coatings. In addition, it is of clinical interest to promote peri-implant bone formation and to restore bony structure in low bone-mass patients. The present study evaluated a combination of an anti-resorptive zoledronic acid (ZOL) implant-coating and a systemically applied sclerostin antibody, a known bone anabolic treatment principle, versus sole sclerostin antibody treatment or ZOL implant-coating in a rat osteoporosis model. Uncoated reference surface implants or ZOL-coated implants (n = 64/group) were inserted into the proximal tibia of aged osteoporotic rats three months following ovariectomy. 32 animals of each group received once weekly sclerostin antibody therapy. Osseointegration was assessed 2 or 4 weeks post-implantation by ex vivo µCT, histology and biomechanical testing. Overall implant survival rate was 97 %. Histomorphology revealed pronounced bone formation along the entire implant length of ZOL-coated implants. At 4 weeks following implant insertion, bone-implant contact, cancellous bone mineral density and bone volume/tissue volume were significantly increased for the combination of ZOL and sclerostin antibody as compared to sclerostin antibody or ZOL implant-coating alone. Removal torque was also significantly increased in the combination therapy group relative to animals receiving only sclerostin antibody therapy or ZOL-coated implants. In an osteoporotic rat model, the combination of anti-resorptive ZOL implant-coating and systemically applied sclerostin antibody led to significantly increased peri-implant bone formation. Therefore, the combination of ZOL and the osteoanabolic sclerostin antibody was more effective than either agent alone.

Item Type: Article
Keywords: Dental implant, osseointegration, osteoporosis animal model, sclerostin antibody, zoledronic acid
Date Deposited: 23 Jul 2019 00:45
Last Modified: 23 Jul 2019 00:45
URI: https://oak.novartis.com/id/eprint/37581

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.